Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 5106

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors Novartis (ruxolitinib)
  Royal College of Physicians
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Blood Cancer UK
  Leukaemia CARE
  MPN Voice
Associated public health groups None
Comparator companies Aspen Pharma Trading (busulfan) - confidentially agreement not signed, not participating
  Aspire Pharma (peginterferon alfa-2a) - confidentially agreement not signed, not participating
  Aurobindo Pharma-Milpharm (anagrelide) - confidentially agreement not signed, not participating
  Bristol-Myers Squibb (hydroxycarbamide) - confidentially agreement not signed, not participating
  Dr Reddy’s Laboratories (anagrelide) - confidentially agreement not signed, not participating
  Glenmark Pharmaceuticals (anagrelide) - confidentially agreement not signed, not participating
  Kent Pharma (anagrelide) - confidentially agreement not signed, not participating
  Medac (hydroxycarbamide) - confidentially agreement not signed, not participating
  Mylan (anagrelide) - confidentially agreement not signed, not participating
  Sandoz (anagrelide) - confidentially agreement not signed, not participating
  Takeda UK (anagrelide) - confidentially agreement not signed, not participating
  Zentiva (anagrelide) - confidentially agreement not signed, not participating
General commentators Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
12 July 2023 Committee meeting: 2
02 June 2023 - 23 June 2023 Draft guidance
11 May 2023 Committee meeting
15 July 2022 Invitation to participate
30 June 2022 - 07 July 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
30 June 2022 In progress
27 March 2015 Draft scope documents
27 August 2014 - 24 September 2014 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: TA356

For further information on our processes and methods, please see our CHTE processes and methods manual